Reid Hoffman is closing a major chapter at Microsoft and opening another in artificial intelligence. The LinkedIn co-founder is stepping down from Microsoft’s board of directors to devote more time to Manas, his AI drug discovery startup.
For Hoffman, the move is more than a routine board reshuffle. It signals where one of Silicon Valley’s most influential operators sees the next big opportunity: using AI to speed up how new medicines are discovered, tested, and brought closer to patients.
Reid Hoffman exits Microsoft board after a hugely profitable run
Hoffman has had a front-row seat to one of Microsoft’s strongest eras. He joined the board after Microsoft acquired LinkedIn in 2016 in a deal worth $26.2 billion. Since then, Microsoft has grown into an AI and cloud powerhouse, helped by Azure, enterprise software, gaming, and its deep partnership with OpenAI.
That board seat also came during a period when Microsoft’s market value climbed dramatically. Hoffman’s decade-long association with the company has been highly lucrative, both reputationally and financially, while keeping him tied to one of the most important AI strategies in Big Tech.
Now, he appears ready to trade the boardroom for the builder’s chair.
Why Hoffman is going into founder mode with Manas
The phrase founder mode has become a shorthand in tech circles for being hands-on, restless, and deeply involved in the daily mechanics of building a company. That seems to be the direction Hoffman is taking with Manas, an AI-driven drug discovery startup focused on developing new treatments faster and more efficiently.
Drug discovery is notoriously slow, expensive, and risky. It can take years and billions of dollars to move from early research to an approved medicine. AI companies like Manas are trying to change that by using machine learning to identify promising compounds, predict biological responses, and reduce some of the guesswork that has long defined pharmaceutical research.
Hoffman’s decision suggests he wants to spend less time advising from the sidelines and more time shaping a company that sits at the intersection of AI, healthcare, and biotech.
Manas AI and the race to reinvent drug discovery
Manas is entering one of the hottest corners of artificial intelligence. AI drug discovery has attracted major investor attention as startups and pharmaceutical giants look for ways to shorten development timelines and improve success rates.
The appeal is clear. If AI can help researchers identify better drug candidates earlier, avoid dead ends, and make smarter decisions in the lab, the impact could be enormous. It could also become a very large business. Healthcare remains one of the sectors where AI has the potential to move beyond productivity tools and into life-changing applications.
Hoffman brings more than capital to the table. As a co-founder of LinkedIn, an early backer of OpenAI, and a longtime Microsoft board member, he has deep experience in scaling networks, backing frontier technology, and navigating the politics of platform power.
What Reid Hoffman’s Microsoft departure means for AI
Hoffman leaving Microsoft’s board does not mean he is walking away from AI. If anything, it shows he is doubling down on it in a more direct way. Microsoft has already become one of the defining companies of the generative AI boom, largely because of its OpenAI partnership and rapid integration of AI tools across products such as Copilot, Office, Windows, and Azure.
By stepping away, Hoffman may also avoid potential conflicts as Manas develops its own AI systems, partnerships, and healthcare ambitions. That matters in a market where cloud providers, AI labs, biotech firms, and investors often overlap.
The wider message is hard to miss: AI’s next major chapter may not be limited to chatbots, search, or workplace software. Some of the biggest bets are moving into science, medicine, and biology.
A high-profile bet on the future of AI healthcare
Reid Hoffman’s move from Microsoft’s board to Manas puts a familiar tech figure in a much more focused role. It also adds credibility to the idea that AI drug discovery could become one of the most consequential areas of the AI economy.
There is plenty still to prove. AI has not magically solved the brutal realities of clinical trials, regulation, or biology. But with Hoffman choosing to spend his time building in this space, Manas is now a startup to watch closely.
Tags: #ReidHoffman #Microsoft #ManasAI #AIDrugDiscovery #ArtificialIntelligence